Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23009686 | 0.82 | CRBN (0.40) | CRBNSIGMAR1DDB1NPSR1HPGD | |
| SCHEMBL30310728 | 0.81 | GRIN1 (0.36) | GRIN1GRIN2AGRIN2BHSD17B10OPRM1 | |
| SCHEMBL8523550 | 0.81 | GRIN1 (0.36) | GRIN1GRIN2AGRIN2BHSD17B10OPRM1 | |
| SCHEMBL13543073 | 0.79 | HSD17B10 (0.57) | CRBNSIGMAR1DDB1HSD17B10NAMPT | |
| SCHEMBL16751001 | 0.76 | GRIN1 (0.32) | GRIN1GRIN2AGRIN2B | |
| SCHEMBL21225273 | 0.74 | GRIN1 (0.38) | GRIN1GRIN2AGRIN2BHSD17B10OPRM1 | |
| SCHEMBL19852917 | 0.72 | JAK3 (0.34) | GRIN1GRIN2AGRIN2BHSD17B10OPRM1 | |
| SCHEMBL19852924 | 0.72 | DRD2 (0.31) | GRIN1GRIN2AGRIN2B | |
| SCHEMBL24339081 | 0.72 | GRIN1 (0.30) | GRIN1GRIN2AGRIN2B | |
| SCHEMBL22213479 | 0.72 | OPRK1 (0.45) | CRBNDDB1NPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333627-B | Substituted 2-hydro-pyrazole derivatives as anticancer agents | 正大天晴药业集团股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-3269715-B1 | SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-9969719-B2 | Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-05-15 | — | — | US | disclosed |
| US-9969719-B2 | Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-05-15 | — | — | US | disclosed |
| US-20180072707-A1 | SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
| US-20180072707-A1 | SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
| WO-2016141881-A1 | SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG | 南京明德新药研发股份有限公司 | 2016-09-15 | — | — | WO | disclosed |
| US-20110118239-A1 | PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4]NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS | TARGACEPT, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| EP-2242364-A1 | PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIROÝ4.4¨NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS | Targacept Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009091561-A1 | PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS | TARGACEPT, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072707-A1 | SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG | CDK4, CDK6, CDK3 | CRBN 732/4885SIGMAR1 4447/4885GRIN1 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.